Immunosuppressive treatment and radiotherapy in kidney transplant patients: A systematic review

Table 3 Characteristics of included studies

Ref.	Study design	Patients (n)	Mean age	Type of cancer	Intervention	Patient survival	Graft survival
Binsaleh et al[15], 2011	Retrospective	9	55 (range: 40-72)	PCa	RT (60-66 Gy); 3 patients had their immunosuppressive regimen changed to a sirolimus-based therapy, while 6 had “judicious” reductions of CNI dosages	NR	4/9 failure; 5/9 good
Pettenati et al[20], 2016	Retrospective	6	63.5 yr (± 7.2)	PCa	RT (EBRT: 76 Gy; IRT: 145 Gy) +Immunosuppressive therapy [2 pts: CNI + AZA + steroids; 19 pts: CNI + MMF + Steroids; 2 pts: MMF, mTORI + Steroids]	1 patient died of PCa	No graft loss nor change in renal function due to PCa treatment
Antunes et al[13], 2018	Retrospective	29	53.4 (±10,7)	PCa	RT in 5 patients (details not reported)	1-yr: 86.2%5-yr: 86.2%10-yr: 79.3%	No patient undergoing RT had allograft failure
Oh et al[26], 2019	Retrospective	13	66 (range: 42-80)	PCa	RT (EBRT: 78 Gy; IRT: 144 Gy) + Immunosuppressive therapy [CIA (n = 8), MMF (n = 13), AZA (n = 3), tacrolimus (n = 12), sirolimus (n = 9), and/or prednisone (n = 20)]	3 yr: 93.8%	NR
Tasaki et al[21], 2019	Retrospective	3	65 (range: 60-67)	PCa	RT (IRT: 145 Gy) + Immunosuppressive therapy [2 pts: CIA + MMF + MP; 1 pt: tacrolimus + MMF +MP]	NR	2 pts good graft function; 1 pt declined graft function after 2 yr
Velvet et al[27], 2019	Retrospective	3	59.5	Lymphoma	RT (details not reported) + reduced immunosuppressive regimen	6 mo: 66.6%	NR

CNI: Calcineurin inhibitor; mTOR: Mammalian target of rapamycin; NR: Not reported; PCa: Prostate cancer; RT: Radiotherapy; EBRT: External beam RT; IRT: Interventional RT.